AirNexis

AirNexis is a biotechnology company focused on developing next-generation inhaled therapies for respiratory and systemic diseases. The company utilizes its proprietary NEXIS platform, a high-efficiency nebulization technology, to deliver complex therapeutics directly to the lungs. This platform is designed to enable the administration of biologics, peptides, and small molecules that typically require systemic injection, thereby improving patient convenience and local drug concentration. AirNexis is particularly focused on the application of inverse agonists for the treatment of chronic asthma, a field pioneered by its scientific founders. The company's goal is to transform the standard of care for pulmonary conditions through advanced drug-device combination products.